(Reuters) -Danish drugmaker Novo Nordisk and Omeros have signed a licensing deal worth up to $2.1 billion for the U.S.-based company's experimental drug, which is being developed for rare blood and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback